Refile: BUZZ-Histogen: Jumps as FDA removes clinical hold on tissue defect treatment study

Histogen

15/03/2021 12:46

(Adds Reuters instrument code)
    ** Regenerative medicine maker's  HSTO.O  shares jump 14.8%
to $1.55 premarket
    ** Co says U.S. FDA has removed clinical hold on its
application to start human trials for HST-003, co's treatment
for cartilage defects in the knee  urn:newsml:reuters.com:*:nGNX6lx4gy
    ** Says FDA's decision means HSTO can begin planned
early-stage trial of HST-003 to evaluate safety and efficacy
    ** Expect to begin trial in Q2 2021, using funding provided
by a $2 mln grant from the Department of Defense - CEO Richard
Pascoe
    ** HST-003 is an anti-inflammatory treatment that stimulates
growth of stem cells in damaged areas to induce tissue
regeneration 
    ** HSTO stock up ~78% this year, as of last close

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))